Health Care · Pharmaceutical Preparations

PBYI PUMA BIOTECHNOLOGY, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1401667118 filings
Russell 2000

PBYI at a glance

PUMA BIOTECHNOLOGY, INC. (PBYI, SEC CIK 1401667) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PUMA BIOTECHNOLOGY, INC. (PBYI) reported revenue of $228.4 million (down 0.9% from FY2024) and net income of $31.1 million. Diluted EPS was $0.61.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding PUMA BIOTECHNOLOGY, INC. (PBYI) shares worth $163.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MILLER MICHAEL PATRICK on November 11, 2026 of 15,000 shares at $8.10 per share.
  • In the last 90 days, PBYI insiders reported 0 open-market purchases ($0) and 3 open-market sales ($734K) on Form 4, a net sale of $734K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$228.4M
−0.9% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$734K
13F holders
24 funds
$163.7M · −2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Unknown or currently immaterial risks could still materially affect results
  • Forward-looking statements remain subject to actual results differing materially from expectations

Management Discussion & Analysis

  • Quarterly revenue $55.1M, up from $54.5M YoY, driven by product revenue of $54.1M vs $51.9M
  • Product revenue best performer, up $2.2M; royalty revenue weakest, $0.9M vs $2.6M
  • Gross margin 72.4% vs 77.6% YoY; net margin 10.8% vs 16.2%
  • Operating cash flow $31.6M for nine months vs $27.4M; cash $41.5M plus securities $67.0M
  • Alisertib spending rising; debt fully repaid, while tariffs and China royalty-rate reduction remain headwinds

AI summary of the PBYI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Full financial results and management commentary provided in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 product revenue $54.1M, up from $51.9M, signaling higher NERLYNX demand despite gross-to-net pressure
  • Q3 net income $6.0M versus $8.8M, while R&D increased to $18.3M to support alisertib trials
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $56.5M, up from $52.4M, led by NERLYNX product revenue of $53.6M versus $49.2M
  • Q2 GAAP net income $8.2M, or $0.16 per diluted share, versus $5.9M and $0.12

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for the quarter ended June 30, 2026 announced
  • Full operating results and management commentary available in Exhibit 99.1 press release
Filed Jun 16, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders re-elected all eight director nominees for one-year terms through the 2027 annual meeting
  • KPMG LLP ratified as independent auditor for fiscal 2026, with 42,612,940 votes supporting

AI summaries of PBYI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PBYI

Don't miss the next PBYI filing

  • Alerts as it files. A push when PBYI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PBYI, by share count.
  • Ask anything. An AI agent that reads every PBYI filing and answers with sources.

PBYI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MILLER MICHAEL PATRICKSellNov 11, 2026$8.10
Cesano AlessandraMSep 14, 2026$2.93
Cesano AlessandraMSep 14, 2026-
WILSON TROY EDWARDSellSep 14, 2026$9.10
Cesano AlessandraSellSep 14, 2026$9.12
HUNT DOUGLAS MSellJul 6, 2026$8.26
NOUGUES MAXIMO FSellJul 6, 2026$8.26
AUERBACH ALAN HSellJul 6, 2026$8.26

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$230.5M$228.4M
Operating Income-$31.0M$37.3M
Net Income$21.6M$30.3M$31.1M
Op. Margin-13.4%16.3%
Net Margin-13.1%13.6%
Balance Sheet
Total Assets-$213.3M$216.3M
Equity$53.4M$92.1M$130.3M
ROE40.4%32.9%23.9%
Per Share
EPS$0.45$0.62$0.61
Cash Flow
Operating CF-$38.9M$41.8M
CapEx$140K$56K$71K

Source: XBRL data in PUMA BIOTECHNOLOGY, INC. (PBYI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PBYI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PBYI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$163.7M
Q2 202626$135.8M
Q1 202627$109.9M
Q4 202524$95.1M
Q3 202526$76.9M
Q2 202524$51.3M
Q1 202522$33.2M
Q4 202418$31.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PBYI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
10-QNov 9, 2026Analysis
8-KNov 5, 2026Analysis-
4Sep 16, 2026--
4Sep 16, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 8, 2026--
4Jul 8, 2026--
4Jul 8, 2026--
8-KJun 16, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
10-KFeb 26, 2026-
8-KFeb 26, 2026Analysis-
4Feb 20, 2026-
4Feb 20, 2026-
4Feb 20, 2026-

Related Health Care companies

All Health Care →

PBYI SEC filings: frequently asked questions

Are PBYI insiders buying or selling?

In the last 90 days, PUMA BIOTECHNOLOGY, INC. (PBYI) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $733,951 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PBYI stock?

As of September 30, 2026, the largest PUMA BIOTECHNOLOGY, INC. (PBYI) holders among the 13F filers tracked by SignalX were BlackRock ($41.8 million), Vanguard Portfolio Management LLC ($18.8 million), Renaissance Technologies LLC ($18.7 million), Vanguard Capital Management LLC ($18.4 million), Dimensional Fund Advisors ($15.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PBYI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PUMA BIOTECHNOLOGY, INC. (PBYI) reported revenue of $228.4 million (down 0.9% from FY2024) and net income of $31.1 million. Diluted EPS was $0.61. The figures come from the XBRL data in the 10-K.

What did PBYI report in its latest 8-K?

PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

What are the latest PBYI SEC filings?

PUMA BIOTECHNOLOGY, INC. (PBYI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is PBYI's SEC CIK number?

PUMA BIOTECHNOLOGY, INC. (PBYI)'s SEC Central Index Key (CIK) is 1401667. EDGAR lists every PBYI filing under that number.

Ask anything about PBYI

The research agent reads PBYI's filings, financials, insider trades and 13F holders, then answers with sources.